Actinium Pharmaceuticals Obtains $5,100,000 New Funding Round

  • Feed Type
  • Date
    12/28/2012
  • Company Name
    Actinium Pharmaceuticals
  • Mailing Address
    501 Fifth Avenue New York, NY 10017
  • Company Description
    Actinium Pharmaceuticals, Inc. (API) is a privately held biopharmaceutical company specialized in the development of cancer drugs. The Company’s product candidates are based on its patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of alpha emitting radioisotopes, the most potent cancer killing agents in existence. API’s first drug for the treatment of acute myeloid leukemia (AML) has been administered to 49 patients with promising results and the second generation drug candidate is currently in clinical trials with 15 patients treated to date.
  • Website
    http://www.actiniumpharmaceuticals.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $5,100,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Funding will be used primarily for further development of Actimab-A, Actinium’s lead drug candidate in multicenter Phase I/II trials in Acute Myeloid Leukemia (AML) and Iomab – B, a Phase II clinical stage bone marrow conditioning agent for preparing patients for hematopoietic stem cell transplantation.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.